These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 16562994)

  • 1. Generation and selection of novel estrogen receptor ligands using the de novo structure-based design tool, SkelGen.
    Firth-Clark S; Willems HM; Williams A; Harris W
    J Chem Inf Model; 2006; 46(2):642-7. PubMed ID: 16562994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. De novo ligand design to partially flexible active sites: application of the ReFlex algorithm to carboxypeptidase A, acetylcholinesterase, and the estrogen receptor.
    Firth-Clark S; Kirton SB; Willems HM; Williams A
    J Chem Inf Model; 2008 Feb; 48(2):296-305. PubMed ID: 18232679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular complexity analysis of de novo designed ligands.
    Boda K; Johnson AP
    J Med Chem; 2006 Oct; 49(20):5869-79. PubMed ID: 17004702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural and chemical basis for enhanced affinity and potency for a large series of estrogen receptor ligands: 2D and 3D QSAR studies.
    Salum Lde B; Polikarpov I; Andricopulo AD
    J Mol Graph Model; 2007 Sep; 26(2):434-42. PubMed ID: 17349808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis of 3-alkyl naphthalenes as novel estrogen receptor ligands.
    Fang J; Akwabi-Ameyaw A; Britton JE; Katamreddy SR; Navas F; Miller AB; Williams SP; Gray DW; Orband-Miller LA; Shearin J; Heyer D
    Bioorg Med Chem Lett; 2008 Sep; 18(18):5075-7. PubMed ID: 18722117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in de novo design strategy for practical lead identification.
    Honma T
    Med Res Rev; 2003 Sep; 23(5):606-32. PubMed ID: 12789688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A structure-guided approach to an orthogonal estrogen-receptor-based gene switch activated by ligands suitable for in vivo studies.
    Kinzel O; Fattori D; Muraglia E; Gallinari P; Nardi MC; Paolini C; Roscilli G; Toniatti C; Gonzalez Paz O; Laufer R; Lahm A; Tramontano A; Cortese R; De Francesco R; Ciliberto G; Koch U
    J Med Chem; 2006 Sep; 49(18):5404-7. PubMed ID: 16942012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-based approach for the study of estrogen receptor binding affinity and subtype selectivity.
    Salum LB; Polikarpov I; Andricopulo AD
    J Chem Inf Model; 2008 Nov; 48(11):2243-53. PubMed ID: 18937440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel estrogen receptor ligands based on an anthranylaldoxime structure: role of the phenol-type pseudocycle in the binding process.
    Minutolo F; Antonello M; Bertini S; Ortore G; Placanica G; Rapposelli S; Sheng S; Carlson KE; Katzenellenbogen BS; Katzenellenbogen JA; Macchia M
    J Med Chem; 2003 Sep; 46(19):4032-42. PubMed ID: 12954056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining protein modeling and 6D-QSAR. Simulating the binding of structurally diverse ligands to the estrogen receptor.
    Vedani A; Dobler M; Lill MA
    J Med Chem; 2005 Jun; 48(11):3700-3. PubMed ID: 15916421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tagged fragment method for evolutionary structure-based de novo lead generation and optimization.
    Liu Q; Masek B; Smith K; Smith J
    J Med Chem; 2007 Nov; 50(22):5392-402. PubMed ID: 17918924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promising core structure for nuclear receptor ligands: design and synthesis of novel estrogen receptor ligands based on diphenylamine skeleton.
    Ohta K; Chiba Y; Ogawa T; Endo Y
    Bioorg Med Chem Lett; 2008 Sep; 18(18):5050-3. PubMed ID: 18760603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of an agonist ligand for estrogen-related receptors ERRbeta/gamma.
    Yu DD; Forman BM
    Bioorg Med Chem Lett; 2005 Mar; 15(5):1311-3. PubMed ID: 15713377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LEA3D: a computer-aided ligand design for structure-based drug design.
    Douguet D; Munier-Lehmann H; Labesse G; Pochet S
    J Med Chem; 2005 Apr; 48(7):2457-68. PubMed ID: 15801836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving structure-based virtual screening by multivariate analysis of scoring data.
    Jacobsson M; Lidén P; Stjernschantz E; Boström H; Norinder U
    J Med Chem; 2003 Dec; 46(26):5781-9. PubMed ID: 14667231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flux (1): a virtual synthesis scheme for fragment-based de novo design.
    Fechner U; Schneider G
    J Chem Inf Model; 2006; 46(2):699-707. PubMed ID: 16563000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Designing active template molecules by combining computational de novo design and human chemist's expertise.
    Lameijer EW; Tromp RA; Spanjersberg RF; Brussee J; Ijzerman AP
    J Med Chem; 2007 Apr; 50(8):1925-32. PubMed ID: 17367122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A critical assessment of docking programs and scoring functions.
    Warren GL; Andrews CW; Capelli AM; Clarke B; LaLonde J; Lambert MH; Lindvall M; Nevins N; Semus SF; Senger S; Tedesco G; Wall ID; Woolven JM; Peishoff CE; Head MS
    J Med Chem; 2006 Oct; 49(20):5912-31. PubMed ID: 17004707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SYNOPSIS: SYNthesize and OPtimize System in Silico.
    Vinkers HM; de Jonge MR; Daeyaert FF; Heeres J; Koymans LM; van Lenthe JH; Lewi PJ; Timmerman H; Van Aken K; Janssen PA
    J Med Chem; 2003 Jun; 46(13):2765-73. PubMed ID: 12801239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NovoFLAP: A ligand-based de novo design approach for the generation of medicinally relevant ideas.
    Damewood JR; Lerman CL; Masek BB
    J Chem Inf Model; 2010 Jul; 50(7):1296-303. PubMed ID: 20586434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.